Search hospitals > Kansas > Mission
University of Kansas Hospital-Westwood Cancer Center
Claim this profileMission, Kansas 66205
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Leukemia
Conducts research for Tumors
Conducts research for Non-Small Cell Lung Cancer
343 reported clinical trials
41 medical researchers
Summary
University of Kansas Hospital-Westwood Cancer Center is a medical facility located in Mission, Kansas. This center is recognized for care of Cancer, Breast Cancer, Leukemia, Tumors, Non-Small Cell Lung Cancer and other specialties. University of Kansas Hospital-Westwood Cancer Center is involved with conducting 343 clinical trials across 466 conditions. There are 41 research doctors associated with this hospital, such as Jun Zhang, Gary C. Doolittle, Chao H. Huang, and Andrea D. Jewell.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Jun ZhangHouston Methodist Hospital4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
23 reported clinical trials
38 drugs studied
Gary C. DoolittleHaysMed University of Kansas Health System3 years of reported clinical research
Studies Cancer
Studies Melanoma
18 reported clinical trials
29 drugs studied
Chao H. HuangUniversity of Kansas Health System Saint Francis Campus5 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
18 reported clinical trials
30 drugs studied
Andrea D. JewellUniversity of Kansas Cancer Center4 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
16 reported clinical trials
38 drugs studied
Clinical Trials running at University of Kansas Hospital-Westwood Cancer Center
Breast Cancer
Prostate Cancer
Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Lung Cancer
Bladder Cancer
Lymphoma
Leukemia
Colorectal Cancer
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Recruiting4 awards Phase 3
Giredestrant + Everolimus
for Advanced or Metastatic Breast Cancer
This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.
Recruiting2 awards Phase 37 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Kansas Hospital-Westwood Cancer Center?
University of Kansas Hospital-Westwood Cancer Center is a medical facility located in Mission, Kansas. This center is recognized for care of Cancer, Breast Cancer, Leukemia, Tumors, Non-Small Cell Lung Cancer and other specialties. University of Kansas Hospital-Westwood Cancer Center is involved with conducting 343 clinical trials across 466 conditions. There are 41 research doctors associated with this hospital, such as Jun Zhang, Gary C. Doolittle, Chao H. Huang, and Andrea D. Jewell.
Where is University of Kansas Hospital-Westwood Cancer Center located?
The University of Kansas Hospital-Westwood Cancer Center is situated at 2650 Shawnee Mission Parkway, Westwood, KS 66205.
Who should I call to ask about financial aid or insurance network?
The University of Kansas Hospital-Westwood Cancer Center offers financial assistance for eligible patients. Organizations such as the Cancer Financial Assistance Coalition, Family Reach Emergency Relief, Komen Treatment Assistance Program, and RX Assist provide aid for cancer treatment costs. For broader healthcare financial assistance, Lawrence Memorial Hospital Financial Assistance, Heartland Community Health Center, and Patient Advocate Foundation offer support. Patients can manage their healthcare needs online via MyChart, including accessing medical records, communicating with doctors, ordering prescriptions, and paying medical bills.
What insurance does University of Kansas Hospital-Westwood Cancer Center accept?
The University of Kansas Cancer Center accepts a variety of insurance plans, such as Aetna CareLink, BCBS Kansas, Sunflower or Home State/Ambetter, Oscar, and Blue Cross Blue Shield of Kansas City/Blue Select. Patients are advised to inform the hospital of any insurance changes via MyChart, the customer service line, or during check-in to ensure coverage and avoid unexpected costs. It's crucial to verify coverage with individual physicians, as some may not participate in the same insurance plans as the hospital.
What awards or recognition has University of Kansas Hospital-Westwood Cancer Center received?
The University of Kansas Cancer Center is recognized by the National Cancer Institute (NCI) with its highest level of recognition, Comprehensive status. This prestigious designation is supported by a five-year, $13.8 million grant for research programs, shared equipment, and resources. The center boasts nearly 350 researchers and 150 disease-specific oncologists, contributing an estimated $2.5 billion in economic impact to the region.